Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Illuccix Total Body PET-CT Imaging in Prostate Cancer
NCT05558956Phase 1Unknown
- Sponsor
- BAMF Health
- Start
- Nov 2022
- Primary completion
- Dec 2023
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 1, open-label trial of gallium ga-68 gozetotide in prostate cancer (PCa) (2 arms), sponsored by BAMF Health. Primary endpoint: Imaging quality at 3 months. Status: unknown.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT05558956.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05558956.